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Abstract
Background: Recent studies demonstrated an association of STAT4 variants with systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA), indicating that multiple autoimmune diseases share common susceptibility genes. We therefore
investigated the influence of STAT4 variants on the susceptibility and phenotype of inflammatory bowel diseases (IBD) in a
large patient and control cohort.
Methodology/Principal Findings: Genomic DNA from 2704 individuals of Caucasian origin including 857 patients with
Crohn’s disease (CD), 464 patients with ulcerative colitis (UC), and 1383 healthy, unrelated controls was analyzed for seven
SNPs in the STAT4 gene (rs11889341, rs7574865, rs7568275, rs8179673, rs10181656, rs7582694, rs10174238). In addition, a
detailed genotype-phenotype analysis was performed. Our analysis revealed an association of the STAT4 SNP rs7574865
with overall decreased susceptibility to CD (p=0.047, OR 0.86 [95% CI 0.74–0.99]). However, compared to CD patients
carrying the wild type genotype, the STAT4 SNP rs7574865 was significantly associated with early CD onset (p=0.021) and
colonic CD (p=0.008; OR=4.60, 95% CI 1.63–12.96). For two other STAT4 variants, there was a trend towards protection
against CD susceptibility (rs7568275, p=0.058, OR 0.86 [95% CI 0.74–1.00]; rs10174238, p=0.057, OR 0.86 [95% CI 0.75–
1.00]). In contrast, we did not observe any association with UC susceptibility. Evidence for weak gene-gene interaction of
STAT4 with the IL23R SNP rs11209026 was lost after Bonferroni correction.
Conclusions/Significance: Our results identified the STAT4 SNP rs7574865 as a disease-modifying gene variant in colonic
CD. However, in contrast to SLE and RA, the effect of rs7574865 on CD susceptibility is only weak.
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Introduction
The precise etiology of inflammatory bowel disease (IBD) is not
completely understood but accumulating data on genetic risk
factors, including genome-wide association studies, have signifi-
cantly advanced our understanding of its pathogenesis. [1,2]
During the last decade, substantial progress has been made in
identifying susceptibility genes for Crohn’s disease (CD) involved
in innate immunity (particularly genetic variants in the NOD2/
CARD15 region) [3–7] and autophagy (variants in the ATG16L1
[8–11] and IRGM region) [12] as well as in the proinflammatory
IL-23 [13,14] and T-helper cell type 17 (Th17) pathway, [15,16]
highlighting the complex interaction between gut homeostasis,
bacterial recognition and proinflammatory mucosal immune
response in IBD. Moreover, it is now clear that adaptive immune
responses involved in the IBD pathogenesis are more complex
than the traditional dichotomous Th1/Th2 paradigm. Particularly
the identification of the IL-23-Th17 pathway highlights the
importance of T-cell differentiation in maintaining intestinal
immune homeostasis in the pathogenesis of both CD and
ulcerative colitis (UC). [16–18]
STAT4 (signal transducers and activators of transcription-4)
represents a transcription factor transducing IL-12-, IL-23-, and
type 1 interferon-mediated signals into Th1 and Th17 differen-
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[19–23] The requirement for STAT4-dependent cytokine regula-
tion has well been replicated for the pathogenesis of autoimmune
encephalomyelitis, [24,25] rheumatoid arthritis, [26,27] and also
IBD, [28–30] highlighting a critical role for STAT4 in
autoimmune diseases. [23] Previous studies demonstrated consti-
tutive STAT4 activation in intestinal T cells of CD patients [28]
and an increased expression and activation of IL-12-induced
STAT4 signaling in the mucosa of patients with UC. [29]
Interestingly, STAT4 isoforms differentially regulate Th1 cytokine
production and thereby the severity of IBD. [30] Using a transfer
colitis model, it has been shown that particularly STAT4beta
promotes colonic inflammation and tissue destruction which
correlates with STAT4 isoform-dependent expression of TNF-a
and GM-CSF in vitro and in vivo. [30] A recent in vivo study [31]
demonstrated an impaired development of human Th1 cells in
patients with deficient expression of STAT4.
Investigating the genetic background of STAT4 regulation,
very recent studies suggested a significant association of
genetic variants in the STAT4 gene on chromosome 2q with
systemic lupus erythematosus (SLE) and rheumatoid arthritis
[23,27,32,33] as well as Sjo ¨gren’s disease (SD), [34] systemic
sclerosis, [23,35] psoriasis [36] and also type-1 diabetes, [37] thus
indicating common genetic and molecular pathways in multiple
autoimmune diseases. In patients with IBD, there are so far only
limited data including a study on 700 Spanish IBD patients
reporting a significant association of the STAT4 variant
rs7574865 with both susceptibility to CD and UC. [38] However,
this association has not been replicated in larger patient cohorts
of different ethnic origin and the phenotypic consequences are
unknown so far. We therefore initiated a large genotype-
phenotype analysis including 1321 Caucasian IBD patients (857
patients with CD, 464 patients with UC) and 1383 healthy,
unrelated controls investigating genetic variants in STAT4 as
potential susceptibility genes in IBD and potential phenotypic
consequences.
Methods
Study population and assessment of disease phenotype
The study population (n=2704) consisted of 1321 Caucasian
IBD patients including 857 patients with CD, 464 patients with
UC, and 1383 healthy, unrelated controls. Written, informed
consent was obtained from all patients prior to the study. The
study was approved by the Ethics committee of the Ludwig-
Maximilians-University Munich (Department of Medicine,
Munich-Grosshadern) and adhered to the ethical principles for
medical research involving human subjects of the Helsinki
Declaration (http://www.wma.net/e/policy/b3.htm). For the
diagnosis of CD or UC, established diagnostic guidelines including
endoscopic, radiological, and histopathological criteria were used.
[39] Patients with CD were assessed according to the Montreal
classification [40] based on age at diagnosis (A), location (L), and
behaviour (B) of disease. In patients with UC, anatomic location
was also assessed in accordance to the Montreal classification,
using the criteria ulcerative proctitis (E1), left-sided UC (distal UC;
E2), and extensive UC (pancolitis; E3). Patients with indeterminate
colitis were excluded from the study. Phenotypic characteristics
included demographic data and clinical parameters (behaviour
and anatomic location of IBD, disease-related complications,
previous surgery or immunosuppressive therapy) which were
recorded by investigation of patient charts and a detailed
questionnaire including an interview at time of enrolment. All
phenotypic data were collected blind to the results of the genotypic
data. The demographic characteristics of the IBD study
population are summarized in Table 1.
DNA extraction and genotyping of the STAT4 variants
From all study participants, blood samples were taken and
genomic DNA was isolated from peripheral blood leukocytes using
the DNA blood mini kit from Qiagen (Hilden, Germany)
according to the manufacturer’s guidelines. Seven STAT4 SNPs
(rs11889341, rs7574865, rs7568275, rs8179673, rs10181656,
rs7582694, rs10174238) were genotyped by PCR and melting
curve analysis using a pair of fluorescence resonance energy
transfer (FRET) probes in a LightCyclerH 480 Instrument (Roche
Diagnostics, Mannheim, Germany). The SNP selection was based
on a previous study demonstrating significant associations of these
SNPs with SLE and rheumatoid arthritis. [27] The donor
fluorescent molecule (fluorescein) at 39-end of the sensor probe is
excited at its specific fluorescence excitation wavelength (533 nm)
and the energy is transferred to the acceptor fluorescent molecule
at the 59-end (LightCycler Red 610, 640 or 670) of the anchor
probe. The specific fluorescence signal emitted by the acceptor
molecule is detected by the optical unit of the LightCycler 480
Instrument. The sensor probe is exactly matching to one allele of
each SNP, preferentially to the rarer allele, whereas in the case of
the other allele there is a mismatch resulting in a lower melting
temperature. The total volume of the PCR was 5 ml containing
25 ng of genomic DNA, 16Light Cycler 480 Genotyping Master
(Roche Diagnostics), 2.5 pmol of each primer and 0.75 pmol of
each FRET probe (TIB MOLBIOL, Berlin, Germany). In the case
of rs11889341, rs7574865, rs7568275 and rs8179673, the
concentration of the forward primer, and in the case of
rs7582694, the concentration of the reverse primer, were reduced
to 1.25 pmol. For rs10181656, the concentration of the forward
primer, and for rs10174238 the concentration of the reverse
primer, were reduced to 0.5 pmol. The PCR comprised an initial
Table 1. Demographic characteristics of the IBD study
population.
Crohn’s
disease
N=857
Ulcerative
colitis
n=464
Controls
n=1383
Gender
Male (%) 45.3 47.9 62.6
Female (%) 54.7 52.5 37.4
Age (yrs)
Mean 6 SD 40.2613.2 42.4614.4 45.8610.7
Range 11–81 7–86 18–71
Body mass index
Mean 6 SD 23.164.2 23.964.1
Range 13–40 15–41
Age at diagnosis (yrs)
Mean 6 SD 27.7611.8 32.0613.3
Range 1–78 9–81
Disease duration (yrs)
Mean 6 SD 11.968.6 10.567.7
Range 0–44 1–40
Positive family history
of IBD (%) 16 16.1
doi:10.1371/journal.pone.0010373.t001
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sec, 60 for 10 sec, 72uC for 15 sec). The melting curve analysis
comprised an initial denaturation step (95uC for 1 min), a step
rapidly lowering the temperature to 40uC and holding for 2 min,
and a heating step slowly (1 acquisition/uC) increasing the
temperature up to 95uC and continuously measuring the
fluorescence intensity. The results of melting curve analysis have
been confirmed by analyzing two patient samples for each possible
genotype using sequence analysis. For sequencing, the total
volume of the PCR was 100 ml containing 250 ng of genomic
DNA, 16PCR-buffer (Qiagen, Hilden, Germany), a final MgCl2
concentration of 1.5 mM, 0.2 mM of a dNTP-Mix (Sigma,
Steinheim, Germany), 2.5 units of HotStar Plus Taq
TM DNA
polymerase (Qiagen) and 10 pmol of each primer (TIB MOL-
BIOL). The PCR comprised an initial denaturation step (95uC for
5 min), 35 cycles (denaturation at 94uC for 30 sec, primer
annealing at 60uC for 30 sec, extension at 72uC for 30 sec) and
a final extension step (72uC for 10 min). The PCR products
were purified using the QIAquick PCR Purification Kit
(Qiagen) and sequenced by a commercial sequencing company
(Sequiserve, Vaterstetten, Germany). All sequences of primers and
FRET probes and primer annealing temperatures used for
genotyping and for sequence analysis are given in Tables 2 and
3. The genotype data for 10 IBD-associated IL23R SNPs
(rs1004819, rs7517847, rs10489629, rs2201841, rs11465804,
rs11209026=p.Arg381Gln, rs1343151, rs10889677, rs11209032,
rs1495965) were available from a previous study. [14]
Statistical analyses
For data evaluation, we used the SPSS 13.0 software (SPSS
Inc., Chicago, IL, U.S.A.) and R-2.4.1. (http://cran.r-project.
org). Each genetic marker was tested for Hardy-Weinberg
equilibrium in the control population. Fisher’s exact test was
used for comparison between categorical variables, while
Student’s t test was applied for quantitative variables. Single-
marker allelic tests were performed with Pearson’s x
2 test. All
tests were two-tailed, considering p-values,0.05 as significant.
Odds ratios were calculated for the minor allele at each SNP.
Bonferroni correction was applied for multiple comparisons as
indicated. LD was calculated using the library genetics implement
in R (http://www.r-project.org). We also used R for interaction
analysis using the allelic model. Haplotypes were calculated using
a sliding-window approach varying the window size from 2 to 7
included SNPs and using the option ‘‘hap-logistic’’ as imple-
mented in PLINK (http://pngu.mgh.harvard.edu/,purcell/
plink/).
Results
The STAT4 SNP rs7574865 modulates susceptibility to CD
but not to UC
In all three subgroups (CD, UC, and controls), the allele
frequencies of the STAT4 SNPs rs11889341, rs7574865,
rs7568275, rs8179673, rs10181656, rs7582694 and
rs10174238 were in accordance with the predicted Hardy-
Weinberg equilibrium (Table 4). Overall, we observed no
significant differences in the frequencies of seven SNPs
investigated in UC patients compared to healthy controls
(Table 4). In patients with CD, the analysis revealed a
significant association of the STAT4 SNP rs7574865 with
decreased susceptibility to CD (p=0.047, OR 0.86 [95% CI
0.74–0.99]) (Table 4); however, this significance would have
been lost after Bonferroni correction, which has not been
applied since all seven STAT4 SNP were in very strong linkage
disequilibrium in all three subgroups of the study population
(Supplemental Tables S1, S2, S3) as also described before [27].
Moreover, for two other variants there was a trend towards
association with decreased CD susceptibility (rs7568275,
p=0.058, OR 0.86 [95% CI 0.74–1.00]; rs10174238,
p=0.057, OR 0.86 [95% CI 0.75–1.00]). For all other STAT4
SNPs investigated, we could not demonstrate significant
differences comparing the allele frequencies of CD patients
with those of healthy controls (Table 4). Moreover, analysis of
haplotypes consisting of SNPs within the STAT4 gene did not
detect any significant differences between CD and UC,
respectively, when compared to the control group (Supplemen-
tal Tables S4 and S5).
Table 2. Primer sequences (F: forward primer, R: reverse primer), FRET probe sequences, and primer annealing temperatures used
for STAT4 genotyping.
Polymorphism Primer sequences FRET probe sequences
rs11889341 F: TCATTTTTTTCCACATGTCTAC
R: GAATGGAGTCCAGAAACAAG
TGAACATCTTATTCTTTTACCACTGC-FL
LC610-CTGCTGGGCCAGCTCTGTCA
rs7574865 F: TTATGGAAAATTACATGAGTGTG
GCAAATCTTTGTAAAAAGTCAA
GGTGACCAAAATGTTAATAGTGGT-FL
LC640-ATCTTATTTCAGTGGAATTTCAGGGGAT
rs7568275 F: CCAACAATATTTTAGCCCTAGTCTA
R: AGCCCAAAATCAATAACCAG
ACTTTATATGTTCAGTTAATATTACTTGGT-FL
LC670-CATACTGACCCATGAGTGTTCAATTG
rs8179673 F: GCCATAGAAGTCTTTGAAGCTGA
R: GTTTTTACCAGTTGGCAGCA
AAGTATATATTAAACAAAGGTCCATAACC-FL
LC610-CCATACACATCATCATCATTTTAT*
rs10181656 F: AGTTTTCAAAGTCTAACACTGTG
R: GCTGCCATGTCGAGAGTA
AACTCTTCTCACCCCTTGTACC-FL
LC640-CTACCCTCCTTTGTAGCCTGGCTT
rs7582694 F: AACCTTCCAATGGTTTCTCA
R: AAAGAACAAGCAAACATCCATAG**
GTTGCATACTCTATGTGTCATCCC-FL
LC670-TCATGAATTTGGTGTGGGTAGAACAAT
rs10174238 F: GTTGAGAGAGGAGAATCTGTTGAACC
R: ATGAACAAGACTGTCACTATCGAG
AAGGTAAACAATGATAACGTCTTTTT-FL
LC610-TTTTGAGATAGAGTTTCAATCTGTCACCCA
Note: FL: Fluorescein, LC610: LightCycler-Red 610; LC640: LightCycler-Red 640. The polymorphic position within the sensor probe is underlined. A phosphate is linked to
the 39-end of the acceptor probe to prevent elongation by the DNA polymerase in the PCR.
*The underlined T bases within the rs8179673 anchor probe represent LNA (locked nucleic acid) bases in.
**The underlined C base within the rs7582694 reverse primer differs from the original sequence.
doi:10.1371/journal.pone.0010373.t002
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phenotype
Based onthe significant associationof the STAT4 SNPrs7574865
with the susceptibility to CD, we next performed a detailed
genotype-phenotype analysis in a subgroup of n=622 phenotyp-
ically well-characterized CD patients carrying SNP rs7574865. CD
patients homozygous for rs7574865 showed a significant younger
age at disease onset (23.2 years 67.5) compared to wildtype patients
(27.9 years 612.3; p=0.021) and also heterozygous patients (29.0
years 612.4; p=0.007). In addition, we observed significantly more
male patients in the subcohort of homozygous carriers of the SNP
rs7574865 compared to the wildtype patients (p=0.040) and
heterozygous patients (p=0.005; Table 5). CD patients homozy-
gous for rs7574865 were found to have significantly more frequent
colonic disease compared to wildtype patients (p=0.008) and
heterozygous carriers (p=0.033; Table 6). Moreover, none of the
homozygous carriers demonstrated isolated CD of the terminal
ileum. In contrast, the analysis revealed no significant associations
with other phenotypic disease characteristics such as body mass
index (BMI), incidence of stenoses and fistulas, use of immunosup-
pressive agents, or extraintestinal manifestations (Tables 5 and 6).
Analysis for epistasis with IL23R
Given that IL-23, a cytokine involved in Th17 cell differenti-
ation, activates not only STAT3 but also to a lesser degree STAT4,
we next investigated potential epistasis with the IBD susceptibility
gene IL23R. Analysis for 10 SNPs in the IL23R region which have
previously shown to significantly influence CD susceptibility [14]
found weak interactions between the STAT4 SNPs rs8179673,
rs7582694 and rs10174238 with the coding IL23R SNP
rs11209026=p.Arg181Gln in CD (Supplemental Table S6) but
significance was lost after correction for multiple comparisons.
Interestingly, similar to the effect of the STAT4 SNP rs7574865
shown in this study, the IL23R SNP rs11209026 is protective for
CD susceptibility. However, none of the three STAT4 SNPs with
epistasis to the IL23R SNP rs11209026 were independently
associated with CD, although there was a trend for association
of CD with rs10174238 (rs10174238: p=0.057; rs8179673:
p=0.12; rs7582694: p=0.15; Table 4). Furthermore, no signif-
icant interaction was observed between STAT4 and IL23R SNPs in
UC (Supplemental Table S7).
Discussion
Here, we present the first detailed genotype-phenotype
analysis of STAT4 gene variants in a large Caucasian IBD
cohort. In line with previous reports of significant associations of
genetic variants in the STAT4 gene with the risk for
autoimmune diseases such as SLE, rheumatoid arthritis
[23,27,32] and psoriasis, [23,36] our study could identify the
STAT4 SNP rs7574865 also to be associated with the
susceptibility to CD. However, this association to CD did not
reach the extent of significance or clinical relevance shown for
other CD susceptibility genes such as NOD2/CARD15 and
IL23R [5,13,14,41–43]. For all other STAT4 gene variants
investigated (rs11889341, rs7568275, rs8179673, rs10181656,
rs7582694 and rs10174238), our analysis did not reveal any
significant association with CD or UC susceptibility. However,
there was a trend towards an association in the case of
rs7568275 and rs10174238 in CD, which can be explained by
the strong linkage disequilibrium between all seven STAT4
SNPs [27] investigated in our study. A smaller Spanish study
including 700 IBD patients also reported a significant associa-
tion of the STAT4 variant rs7574865 with CD susceptibility,
although rs7574865 was in this study a risk allele and not
protective [38]. In contrast, a very recent Korean study found
Table 3. Primer sequences used for the sequence analysis of
STAT4 variants.
Polymorphism Primer sequences
rs11889341 CAAATACCTTCTACTCTATGGCT
GAATGGAGTCCAGAAACAAG
rs7574865 AAAGAAGTTTGTAATTAAAAAGCTA
GCAAATCTTTGTAAAAAGTCAA
rs7568275 AAACCAACCTCATTAAATTATAGCA
GAAGACAAAAAGAAAATATGGTCAC
rs8179673 TTAGTTTTTCCCACGTTTAGTTCTC
TCAAATCATATGGGGAGGAGTG
rs10181656 GTGGATAAAAATACAAAATAAAAGAC
GGATTTCAACAGGATCACC
rs7582694 AACCTTCCAATGGTTTCTCA
CAGTGGATATGGATTTTAGTACTCTG
rs10174238 GAGGTAGAGGTTACAGTGAGCCGA
AAGCAATGTTTCACCTGTCCCT
doi:10.1371/journal.pone.0010373.t003
Table 4. Associations of STAT4 gene markers in CD and UC case-control association studies.
SNP Minor allele Crohn’s disease
n=857
Ulcerative colitis
n=464
Controls
n=1383
MAF p value OR [95% CI] MAF p value OR [95% CI] MAF
rs11889341 T 0.194 0.11 0.88 [0.76–1.03] 0.215 0.96 1.01 [0.84–1.20] 0.214
rs7574865 T 0.190 0.047 0.86 [0.74–0.99] 0.214 1.00 1.00 [0.83–1.20] 0.215
rs7568275 G 0.193 0.058 0.86 [0.74–1.00] 0.212 0.78 0.97 [0.81–1.17] 0.217
rs8179673 C 0.198 0.12 0.89 [0.76–1.03] 0.215 0.93 0.99 [0.82–1.18] 0.217
rs10181656 G 0.197 0.12 0.89 [0.76–1.03] 0.211 0.74 0.96 [0.80–1.16] 0.217
rs7582694 C 0.197 0.15 0.89 [0.77–1.04] 0.212 0.89 0.98 [0.82–1.18] 0.215
rs10174238 G 0.202 0.057 0.87 [0.75–1.00] 0.229 0.85 1.02 [0.85–1.22] 0.226
Minor allele frequencies (MAF), allelic test P-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and
UC case-control cohorts.
doi:10.1371/journal.pone.0010373.t004
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of the STAT4 SNP rs925847 with susceptibility to UC
(P=0.025; OR=0.63). [44] Similar to the findings in CD in
our study, STAT4 was protective against UC in the Korean
study. [44] In contrast, another very recent study from Spain
found no association of the STAT4 SNP rs7574865 with CD and
UC [45], while an extended meta-analysis showed a disease
association of this SNP with UC and not CD in the Spanish
population. [45] Consideri n gt h el i m i t e dd a t ao fSTAT4 gene
variants in IBD patients and the conflicting results from the
Spanish studies, the impact of STAT4 on IBD susceptibility
s e e m st ob em u c hm o r el i m i t e dt h a nt h a to fSTAT3 variants.
In addition, this study demonstrated weak epistasis between the
CD-protective IL23R variant rs11209026 with several STAT4
SNPs (Supplementary Table S6). However, none of these gene-
gene interactions remained significant after Bonferroni correction.
Interestingly, similar to our findings, opposing effects of STAT3
variants on different Th17-mediated autoimmune diseases have
been reported. A very recent genome-wide association study
identified STAT3 as a new susceptibility gene for multiple sclerosis
(MS), a disorder in which the Th17 pathway plays a major role.
[46] Remarkably, in MS, the G allele of the STAT3 SNP rs744166
is the risk allele, whereas in CD, the A allele has been found to
increase disease susceptibility. [47] Thus, it is possible that a SNP
can confer opposite effects in different disorders within the same
pathway. Further genotype-phenotype studies in large patient
cohorts of different ethnic origin will therefore be required before
final conclusion on the influence of STAT4 on IBD susceptibility
can be drawn.
In our study, CD patients homozygous for the SNP rs7574865
were significantly younger at disease onset compared to wildtype
and heterozygous patients. Moreover, CD patients homozygous
for rs7574865 were found to have significantly more frequent
colonic disease compared to wildtype patients (p=0.008) and
heterozygous carriers (p=0.033). It is therefore of special interest
that particularly the STAT4 SNP rs7574865, which has previously
shown to be the most significant SNP in the association studies for
other IBD-associated autoimmune diseases such as SLE, rheuma-
toid arthritis [23,27,32] and Sjo ¨gren’s disease, [23,34] is associated
with both CD susceptibility and CD phenotype. However, similar
to STAT4, other IBD susceptibility genes such as IL23R, IL2/IL21,
STAT3, and PTPN2 are associated with other autoimmune
diseases. [48–53]
Regarding the disease-modifying effect of genetic variants in the
STAT4 region on IBD observed in our study, one might
hypothesize whether the STAT4 risk allele has different expression
levels or functional effects in different effector cells. A recent study
demonstrated a significant association of the STAT4 risk allele with
overexpression of STAT4 in primary cells of mesenchymal origin
such as osteoblasts but not in B cells. [54] This might indicate the
potential presence of a tissue-specific intragenic enhancer and cell-
type-specific effects of different STAT4 gene variants on STAT4
expression levels. This would be in line with previous studies
demonstrating that STAT4 isoforms differentially regulate Th1
cytokine production with STAT4b promoting greater colonic
inflammation and tissue destruction which correlates with STAT4
isoform-dependent expression of TNF-a and GM-CSF in vitro and
in vivo, but not Th1 expression of IFN-c or Th17 expression of IL-
17. [30] Further investigations on the effect of genetic variants on
the expression levels and splicing isoforms in both T cells and B
cells as well as intestinal epithelial cells will therefore be necessary.
Moreover, based on previous studies [55] reporting an increased
sensitivity to IFN-a in lupus patients carrying the risk variant of
STAT4, one might also speculate whether this mechanism might
contribute to increased mucosal inflammation in IBD patients and
to the response of immunosuppressive and immunomodulatory
therapies.
In summary, our results identified the STAT4 SNP rs7574865 as
a disease-modifying gene variant in CD. Homozygous carriers of
the minor allele of rs7574865 have an earlier CD onset and more
often colonic disease than carriers of the major allele. Further
studies on expression and regulation of STAT4 in the intestinal
mucosa will be required to investigate the functional consequences
of STAT4 gene variants in more detail.
Table 5. Association between the STAT4 rs7574865 gene variant and demographic characteristics of the CD cohort.
rs7574865
Crohn’s disease
(1)
GG
(n=399)
(2)
GT
(n=203)
(3)
TT
(n=20)
(1) vs. (2)
p value
OR
(1) vs. (3)
p value
OR
(2) vs. (3)
p value
OR
(1) vs. (2+3)
p value
OR
Male sex 203/399 (51.0%) 84/203 (41.0%) 15/20 (75.0%) 0.031 0.040 0.005 0.132
0.68 CI (0.48–0.96) 2.90 CI (1.03–8.12) 4.25 (1.49–12.14) 0.77 (0.56–1.07)
Age (yr)
Mean 6 SD 40.7613.3 42.0612.9 34.467.2 0.225 0.001 0.0002 0.528
Range 16–82 18–82 21–49
Age at diagnosis (yr)
Mean 6 SD 27.9612.3 29.0612.4 23.267.5 0.308 0.021 0.007 0.551
Range 6–71 11–78 13–37
Disease duration (yr)
Mean 6 SD 12.769.1 13.168.4 10.864.3 0.643 0.103 0.067 0.823
Range 0–46 1–42 2–19
BMI
Mean 6 SD 23.264.3 22.864.2 23.463.3 0.312 0.808 0.487 0.366
Range 13–41 16–34 16–29
doi:10.1371/journal.pone.0010373.t005
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40.
rs7574865 (1) (2) (3) (1) vs. (2) (1) vs. (3) (2) vs. (3) (1) vs. (2+3)
GG GT TT p value p value p value p value
Crohn’s disease (n=399) (n=203) (n=20) OR OR OR OR
Age at diagnosis
#16 years (A1) 45/383 (11.7%) 21/193 (10.9%) 4/18 (22.2%) 0.890
0.92 CI (0.53–1.59)
0.256
2.15 CI (0.68–6.80)
0.241
2.34 CI (0.70–7.77)
0.896
0.95 CI (0.56–1.59)
17–40 years (A2) 286/383 (74.7%) 142/193 (73.6%) 14/18 (78.8%) 0.840
0.94 CI (0.94–1.40)
1.000 1.000 0.446
0.86 CI (0.59–1.25)
.40 years (A3) 52/383 (13.6%) 30/193 (15.5%) 0 0.248
1.33 CI (0.82–2.18)
1.19 CI (0.38–3.69)
0.146
1.26 CI (0.40–4.00)
0.083
1.000
0.99 CI (0.61–1.60)
Location
Terminal ileum (L1) 45/385 (11.7%) 31/192 (16.1%) 0 0.151
1.45 CI (0.89–2.38)
0.242 0.082 0.305
1.31 CI (0.80–2.14)
Colon (L2) 37/385 (9.6%) 25/192 (13.0%) 6/18 (33.3%) 0.253
1.41 CI (0.82–2.42)
0.008
4.60 CI (1.63–12.96)
0.033
3.32 CI (1.14–9.64)
0.079
1.63 CI (0.98–2.71)
Ileocolon (L3) 230/385 (59.7%) 115/192 (59.9%) 8/18 (44.4%) 1.000
1.01 CI (0.71–1.43)
0.225
0.54 CI (0.21–1.40)
0.220
0.54 CI (0.20–1.42)
0.794
0.95 CI (0.68–1.34)
Upper GI (L4) 10/385 (2.6%) 0 0 0.035 1.000 - -
Terminal ileum and
Upper GI (L1+L4)
10/385(2.6%) 2/192 (1.0%) 0 0.354
0.39 CI (0.09–1.82)
1.000 1.000 0.230
0.36 CI (0.08–1.66)
Colon and
Upper GI (L2+L4)
4/385 (1.0%) 3/192 (1.6%) 0 0.691
1.51 CI (0.33–6.82)
1.000 1.000 0.702
1.38 CI (0.31–6.23)
Ileocolon and
Upper GI (L3+L4)
49/385 (12.7%) 16/192 (8.3%) 4/18 (22.2%) 0.123
0.62 CI (0.34–1.13)
0.275
1.96 CI (0.62–6.20)
0.076
3.14 CI (0.92–10.68)
0.284
0.72 CI (0.42–1.25)
Behaviour
1
Non-stricturing,
Non-penetrat (B1)
82/369 (22.2%) 45/184 (24.5%) 2/19 (10.5%) 0.592
1.13 CI (0.75–1.72)
0.389
0.41 CI (0.09–1.82)
0.254
0.36 CI (0.08–1.64)
0.835
1.05 CI (0.70–1.59)
with perianal f. (B1p) 8/369 (2.2%) 4/184 (2.2%) 0 1.000
1.00 CI (0.30–3.37)
1.000 1.000 1.000
0.91 CI (0.27–3.05)
Stricturing (B2) 100/369 (27.1%) 39/184 (21.2%) 6/19 (31.6%) 0.146
0.72 CI (0.47–1.10)
0.792
1.24 CI (0.46–3.35)
0.382
1.72 CI (0.61–4.81)
0.228
0.77 CI (0.51–1.15)
with perianal f. (B2p) 10/369 (2.7%) 9/184 (4.9%) 0 0.217
1.85 CI (0.74–4.63)
1.000 1.000 0.330
1.66 CI (0.67–4.17)
Penetrating (B3) 152/369 (41.2%) 81/184 (44.0%) 10/19 (52.6%) 0.584
1.12 CI (0.78–1.60)
0.348
1.59 CI (0.63–4.00)
0.480
1.41 CI (0.55–3.64)
0.427
1.16 CI (0.82–1.64)
with perianal f. (B3p) 17/369 (4.6%) 6/184 (3.3%) 1/19 (5.3%) 0.508
0.70 CI (0.27–1.80)
0.603
1.15 CI (0.14–9.13)
0.503
1.65 CI (0.19–14.45)
0.664
0.74 (0.30–1.81)
Use of immuno-
suppressive agents
307/376 (82.0%) 154/188 (82.0%) 16/20 (80.0%) 1.000
1.01 CI (0.65–1.60)
0.772
0.90 CI (0.29–2.77)
0.767
0.88 CI (0.28–2.81)
1.000
1.00 CI (0.65–1.56)
Use of infliximab 156/397 (39.0%) 80/199 (40.0%) 9/20 (45.0%) 0.859
1.04 CI (0.73–1.47)
0.644
1.26 CI (0.51–3.12)
0.812
1.22 CI (0.48–3.07)
0.796
1.06 CI (0.75–1.48)
Fistula 187/369 (50.7%) 102/184 (55.4%) 11/19 (57.9%) 0.321
1.21 CI (0.85–1.73)
0.641
1.34 CI (0.53–3.40)
1.000
1.10 CI (0.42–2.87)
0.257
1.22 CI (0.87–1.72)
Stenosis 241/364 (66.2%) 123/182 (67.6%) 12/19 (63.2%) 0.773
1.06 CI (0.73–1.55)
0.806
0.87 CI (0.34–2.28)
0.798
0.82 CI (0.31–2.20)
0.853
1.04 CI (0.72–1.50)
Abscesses 112/335 (33.0%) 71/169 (42.0%) 7/19 (37.0%) 0.063
1.44 CI (0.99–2.11)
0.805
1.16 CI (0.44–3.03)
0.807
0.80 CI (0.30–2.14)
0.072
1.41 CI (0.98–2.04)
Surgery because
of CD
219/355 (62.0%) 116/177 (66.0%) 10/18 (56.0%) 0.393
1.18 CI (0.81–1.71)
0.626
0.78 CI (0.30–2.01)
0.442
0.66 CI (0.25–1.75)
0.157
1.34 CI (0.91–1.93)
Positive family
history of IBD
55/291 (18.9%) 17/139 (12.2%) 1/13 (7.7%) 0.098
0.60 CI (0.33–1.07)
0.475
0.36 CI (0.05–2.81)
1.000
0.60 CI (0.07–4.89)
0.060
0.58 CI (0.32–1.02)
For each variable, the number of patients with complete information on this particular disease variable included in the analysis is given.
1Disease behaviour was defined according to the Montreal classification
40. A stricturing disease phenotype was defined as presence of stenosis without penetrating
disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MR enteroclysis).
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, and/or infliximab.
3Only surgery related to CD-specific problems (e.g. fistulectomy, colectomy, ileostomy) was included.
doi:10.1371/journal.pone.0010373.t006
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